Dasar
Spot
Perdagangkan kripto dengan bebas
Perdagangan Margin
Perbesar keuntungan Anda dengan leverage
Konversi & Investasi Otomatis
0 Fees
Perdagangkan dalam ukuran berapa pun tanpa biaya dan tanpa slippage
ETF
Dapatkan eksposur ke posisi leverage dengan mudah
Perdagangan Pre-Market
Perdagangkan token baru sebelum listing
Futures
Akses ribuan kontrak perpetual
TradFi
Emas
Satu platform aset tradisional global
Opsi
Hot
Perdagangkan Opsi Vanilla ala Eropa
Akun Terpadu
Memaksimalkan efisiensi modal Anda
Perdagangan Demo
Pengantar tentang Perdagangan Futures
Bersiap untuk perdagangan futures Anda
Acara Futures
Gabung acara & dapatkan hadiah
Perdagangan Demo
Gunakan dana virtual untuk merasakan perdagangan bebas risiko
Peluncuran
CandyDrop
Koleksi permen untuk mendapatkan airdrop
Launchpool
Staking cepat, dapatkan token baru yang potensial
HODLer Airdrop
Pegang GT dan dapatkan airdrop besar secara gratis
Launchpad
Jadi yang pertama untuk proyek token besar berikutnya
Poin Alpha
Perdagangkan aset on-chain, raih airdrop
Poin Futures
Dapatkan poin futures dan klaim hadiah airdrop
Investasi
Simple Earn
Dapatkan bunga dengan token yang menganggur
Investasi Otomatis
Investasi otomatis secara teratur
Investasi Ganda
Keuntungan dari volatilitas pasar
Soft Staking
Dapatkan hadiah dengan staking fleksibel
Pinjaman Kripto
0 Fees
Menjaminkan satu kripto untuk meminjam kripto lainnya
Pusat Peminjaman
Hub Peminjaman Terpadu
Lainnya
Bio-Techne Corporation (TECH) Carries Attractive FY27 Organic Growth Projections
Bio-Techne Corporation (TECH) Carries Attractive FY27 Organic Growth Projections
Muhammad Ali Khalid
Wed, February 25, 2026 at 4:28 AM GMT+9 2 min read
In this article:
TECH
+4.02%
Bio-Techne Corporation (NASDAQ:TECH) is one of the 10 best life sciences stocks to buy according to hedge funds.
On February 5, Daniel Arias from Stifel Nicolaus reaffirmed his Hold rating on Bio-Techne Corporation (NASDAQ:TECH). He raised the stock’s price target from $60 to $65, implying a double-digit upside potential of 13%.
Pressmaster/Shutterstock.com
Arias noted that despite the company’s second-quarter beat, there are expectations of flat mid-year growth. He also anticipates an unchanged forecast for the coming year, along with a downward adjustment for next quarter.
On February 5, Evercore ISI analyst Daniel Markowitz reiterated an In Line rating for Bio-Techne Corporation (NASDAQ:TECH). He also increased the price target from $62 to $68, resulting in more than 18% upside potential at the current level.
Markowitz reflected on the company’s fourth quarter guidance, which suggests a light market recovery. He believes that the FY27 organic growth projections for the company appear promising for investors.
Bio-Techne Corporation (NASDAQ:TECH) develops and markets life sciences instruments, reagents, precision diagnostics, and related services. The company offers these for clinical research, diagnostics, gene therapy, and bioprocessing markets. Its product portfolio includes antibodies, immunoassay kits, automated protein analysis systems, hematology, and molecular diagnostic kits.
While we acknowledge the potential of TECH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.
Disclosure: None. Follow Insider Monkey on Google News.
Terms and Privacy Policy
Privacy Dashboard
More Info